4 results about "Immune compromised" patented technology

The present disclosure provides an immunodeficient or immune-impaired chimeric non-human animal with a deletion or impairment of adeno-associated virus receptor (AAVR), comprising human hepatocytes, methods for preparing the chimeric non-human animal comprising human hepatocytes and methods of utilizing the chimeric non-human animal comprising human hepatocytes to evaluate transduction efficiency of adeno-associated viruses (AAV), and determine mechanism of inhibition / modification of AAV transduction in human hepatocytes.

The present disclosure provides methods for treating or inhibiting the growth of a tumor, including selecting a patient with cancer, wherein the patient is immunosuppressed or immunocompromised, and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody, such as cemiplimab or a bioequivalent thereof). In certain embodiments, the cancer is skin cancer, such as cutaneous squamous cell carcinoma.

FIELD: occupational medicine.SUBSTANCE: used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase. Samples of venous blood and smears from the mucous membrane of the pharynx are taken. In the presence of Streptococcus pneumoniae DNA in scrapings from the mucous membrane of the pharynx and with the level of immunoglobulin M in the blood serum≤ 1.7 g / l is used to diagnose immunocompromise in workers exposed to mixed aerosols containing crystalline silicon dioxide from 10 to 70% and metals in the solid phase.EFFECT: method provides the possibility of selecting immunocompromised workers exposed to industrial mixed aerosols for priority vaccination against pneumococcal infection at the stage of periodic medical examination, by determining the level of immunoglobulin M in the blood serum and Streptococcus pneumoniae DNA in swabs from the mucous membrane of the pharynx.1 cl, 1 tbl, 1 ex

Systems and methods to genetically modify B cells to express selected antibodies are described. The systems and methods can be used to: obviate the need for classical vaccinations; provide protection against infectious agents for which no vaccinations are currently available; provide protection against infectious agents when patients are otherwise immune-suppressed; and / or provide a benefit provided by a therapeutic antibody, such as in the treatment of autoimmune disorders.